263 related articles for article (PubMed ID: 32912960)
21. Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas.
Willenbacher E; Willenbacher W; Weger R; Dominik W; Manzl C; Brunner A
Ann Hematol; 2020 Sep; 99(9):2125-2132. PubMed ID: 32613279
[TBL] [Abstract][Full Text] [Related]
22. [The role of translocations involving c-MYC/8q24, BCL2/18q21 and/or BCL6/3q27 genes in patients with follicular lymphoma. Retrospective analysis of single - centre data].
Misyurina AE; Kravchenko SK; Kovrigina AM; Magomedova AU; Plastinina LV; Obukhova TN; Misyurin AV; Misyurin VA; Grebenuk LA; Babaeva FE; Baryakh EA; Vorobiev AI
Ter Arkh; 2019 Jul; 91(7):52-62. PubMed ID: 32598736
[TBL] [Abstract][Full Text] [Related]
23. C-MYC and BCL2 translocation frequency in diffuse large B-cell lymphomas: A study of 97 patients.
Akkaya B; Salim O; Akkaya H; Ozcan M; Yucel OK; Erdem R; Iltar U; Undar L
Indian J Pathol Microbiol; 2016; 59(1):41-6. PubMed ID: 26960633
[TBL] [Abstract][Full Text] [Related]
24. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome.
Tibiletti MG; Martin V; Bernasconi B; Del Curto B; Pecciarini L; Uccella S; Pruneri G; Ponzoni M; Mazzucchelli L; Martinelli G; Ferreri AJ; Pinotti G; Assanelli A; Scandurra M; Doglioni C; Zucca E; Capella C; Bertoni F
Hum Pathol; 2009 May; 40(5):645-52. PubMed ID: 19144384
[TBL] [Abstract][Full Text] [Related]
25. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: Biopsy analysis of 70 cases from the Slovak Lymphoma Registry.
Lešková K; Szépe P; Balhárek T; Barthová M; Janáková Ľ; Farkašová A; Plank L
Neoplasma; 2022 Jul; 69(4):957-964. PubMed ID: 35652622
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Significance of
Rosenwald A; Bens S; Advani R; Barrans S; Copie-Bergman C; Elsensohn MH; Natkunam Y; Calaminici M; Sander B; Baia M; Smith A; Painter D; Pham L; Zhao S; Ziepert M; Jordanova ES; Molina TJ; Kersten MJ; Kimby E; Klapper W; Raemaekers J; Schmitz N; Jardin F; Stevens WBC; Hoster E; Hagenbeek A; Gribben JG; Siebert R; Gascoyne RD; Scott DW; Gaulard P; Salles G; Burton C; de Jong D; Sehn LH; Maucort-Boulch D
J Clin Oncol; 2019 Dec; 37(35):3359-3368. PubMed ID: 31498031
[TBL] [Abstract][Full Text] [Related]
27. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
[TBL] [Abstract][Full Text] [Related]
28. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma.
Horn H; Ziepert M; Wartenberg M; Staiger AM; Barth TF; Bernd HW; Feller AC; Klapper W; Stuhlmann-Laeisz C; Hummel M; Stein H; Lenze D; Hartmann S; Hansmann ML; Möller P; Cogliatti S; Pfreundschuh M; Trümper L; Loeffler M; Glass B; Schmitz N; Ott G; Rosenwald A;
Leukemia; 2015 Jul; 29(7):1564-70. PubMed ID: 25687653
[TBL] [Abstract][Full Text] [Related]
29. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P
Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193
[TBL] [Abstract][Full Text] [Related]
30. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
Pedersen MØ; Gang AO; Brown P; Pedersen M; Knudsen H; Nielsen SL; Poulsen T; Wirenfeldt Klausen T; Høgdall E; Nørgaard P
PLoS One; 2017; 12(10):e0186983. PubMed ID: 29088292
[TBL] [Abstract][Full Text] [Related]
31. High-grade B-cell lymphoma with
Scott DW; King RL; Staiger AM; Ben-Neriah S; Jiang A; Horn H; Mottok A; Farinha P; Slack GW; Ennishi D; Schmitz N; Pfreundschuh M; Nowakowski GS; Kahl BS; Connors JM; Gascoyne RD; Ott G; Macon WR; Rosenwald A
Blood; 2018 May; 131(18):2060-2064. PubMed ID: 29475959
[TBL] [Abstract][Full Text] [Related]
32. Lymphomas with pseudo-double-hit BCL6-MYC translocations due to t(3;8)(q27;q24) are associated with a germinal center immunophenotype, extranodal involvement, and frequent BCL2 translocations.
Johnson SM; Umakanthan JM; Yuan J; Fedoriw Y; Bociek RG; Kaiser-Rogers K; Sanmann JN; Montgomery ND
Hum Pathol; 2018 Oct; 80():192-200. PubMed ID: 29902576
[TBL] [Abstract][Full Text] [Related]
33. MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma.
Kawamoto K; Miyoshi H; Yoshida N; Nakamura N; Ohshima K; Sone H; Takizawa J
Cancer Sci; 2016 Jun; 107(6):853-61. PubMed ID: 27027803
[TBL] [Abstract][Full Text] [Related]
34. Mutational, immune microenvironment, and clinicopathological profiles of diffuse large B-cell lymphoma and follicular lymphoma with BCL6 rearrangement.
Carreras J; Ikoma H; Kikuti YY; Miyaoka M; Hiraiwa S; Tomita S; Kondo Y; Ito A; Nagase S; Miura H; Kawada H; Roncador G; Campo E; Hamoudi R; Nakamura N
Virchows Arch; 2024 Apr; 484(4):657-676. PubMed ID: 38462571
[TBL] [Abstract][Full Text] [Related]
35. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
[No Abstract] [Full Text] [Related]
36. Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3.
Borovecki A; Korać P; Nola M; Ivanković D; Jaksić B; Dominis M
Croat Med J; 2008 Oct; 49(5):625-35. PubMed ID: 18925696
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic Approach for Double-Hit and Triple-Hit Lymphoma Based on Immunophenotypic and Cytogenetic Characteristics of Bone Marrow Specimens.
Kim H; Kim HJ; Kim SH
Ann Lab Med; 2020 Sep; 40(5):361-369. PubMed ID: 32311849
[TBL] [Abstract][Full Text] [Related]
38. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.
Wang W; Hu S; Lu X; Young KH; Medeiros LJ
Am J Surg Pathol; 2015 Aug; 39(8):1132-9. PubMed ID: 25828391
[TBL] [Abstract][Full Text] [Related]
39. Detailed molecular analysis and evaluation of prognosis in cases with high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
Stengel A; Kern W; Meggendorfer M; Haferlach T; Haferlach C
Br J Haematol; 2019 Jun; 185(5):951-954. PubMed ID: 30460680
[No Abstract] [Full Text] [Related]
40. A Novel Non-Immunoglobulin (non-Ig)/BCL6 Translocation in Diffuse Large B-Cell Lymphoma Involving Chromosome 10q11.21 Loci and Review on Clinical Consequences of BCL6 Rearrangements.
Jarosova M; Kriegova E; Schneiderova P; Fillerova R; Prochazka V; Mikesova M; Flodr P; Indrak K; Papajik T
Pathol Oncol Res; 2016 Apr; 22(2):233-43. PubMed ID: 26319027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
